Overview

Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial

Status:
Recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

This clinical trial is an investigator-initiated multicenter, open, prospective clinical study in order to explore the efficacy and safety of rituximab plus zanubrutinib and lenalidomide in relapsed and refractory diffuse large B cell lymphoma.

Phase:

Phase 2

Details

Lead Sponsor:

Qingdao Central Hospital

Treatments:

Lenalidomide
Rituximab
Zanubrutinib